GlassScriptPhysician profile
Ray D Wakefield
NPI 1184055345
$8,861.11
in general payments reported to CMS, 2019-2025
39 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,072 · 2022: $1,771 · 2023: $2,268 · 2024: $2,227 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,977 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,976.77 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $982.79 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $953.90 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $884.16 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $831.06 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $704.41 | 2021-2025 | Trintellix |
| Pfizer INC. | $569.92 | 2021-2025 | |
| Lilly USA, LLC | $562.58 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $560.02 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $431.20 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $352.39 | 2022-2025 | Verquvo, Belsomra, Januvia |
| Bayer Healthcare Pharmaceuticals INC. | $244.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $241.88 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $206.53 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.23 | 2023-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $131.48 | 2021-2023 | Freestyle Libre 3 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Wakefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.